Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952472 | 0.92 | F11 (0.35) | PTGS1GRIA4SCN9AXDHTDP1 | |
| SCHEMBL4950102 | 0.91 | PTGS1 (0.41) | GRM5PTGS1SCN5ASCN9AKDM4E | |
| SCHEMBL4950754 | 0.90 | SCN5A (0.37) | GRM5PTGS1SCN5ASCN9AKDM4E | |
| SCHEMBL5141284 | 0.89 | SCN9A (0.47) | GRM5SCN5ASCN9AROCK2ROCK1 | |
| SCHEMBL4950027 | 0.87 | TDP1 (0.39) | PTGS1GRIA4TDP1KDM4E | |
| SCHEMBL4950640 | 0.86 | KDM4E (0.43) | PTGS1GRIA4TDP1KDM4E | |
| SCHEMBL4950718 | 0.85 | RARB (0.41) | PTGS1GRIA4TDP1KDM4E | |
| SCHEMBL4952527 | 0.85 | PTGS2 (0.36) | PTGS1SCN9AXDH | |
| SCHEMBL4950475 | 0.85 | SRD5A2 (0.46) | PTGS1GRIA4TDP1KDM4E | |
| SCHEMBL4950379 | 0.84 | SCN9A (0.37) | GRM5GRIA4SCN5ASCN9AXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | claimed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | claimed |
| EP-1893597-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-03-05 | — | — | EP | claimed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | claimed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | claimed |
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1893597-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | GRM5 24/4885PTGS1 1216/4885GRIA4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.